scm logo

SCM Life Science (KOSDAQ 298060. CEO Lee Byung-gun) announced on the 7th that it recently registered a patent (registration number: 6786554) on the method of stratum separation and proliferation of stem cells with the Japanese Patent Office. The duration of the patent is until 2037. 

Earlier, SCM Life Science entered the KOSDAQ market in June in recognition of various cell therapy technologies such as stem cell separation culture methods. SCM Life Science can produce high-purity stem cell therapy by separating and culturing stem cells with high purity and homogeneity based on its own source technology, the Subfraction Culturing Method.

Existing stem cell treatments have limitations in high treatment costs due to their low purity and lack of disease-specific treatments. On the other hand, SCM Life Science can innovatively increase the purity of stem cells and select cell lines suitable for efficacy markers for each disease through the layer separation culture method. In other words, it means that the treatment efficacy can be maximized by implementing a stem cell treatment tailored to the disease, while the treatment cost can be lowered.

The improved layer separation culture method, which is patented in Japan this time, takes a step further from the existing layer separation culture method and induces rapid proliferation of high-purity stem cells. Due to the low control of culture cell density and the addition of antioxidants, the cell proliferation rate can be effectively improved with less subculture (artificial cell proliferation method that periodically transplants the medium).

SCM Life Science' improved “Subfractionation Culturing Method” law has been registered in Korea and Japan, and the technology is currently undergoing patent registration screening in countries around the world, including the United States, Europe, China, Australia, Indonesia, and Malaysia.

The Japanese patent registration is interpreted as meaning that the technology of “Subfractionation Culturing Method”, a key source technology of SCM Life Science, has been highly recognized not only in Korea but also in Japan. This is because obtaining a patent in Japan can be used as a favorable precedent for securing patent rights in other major patent countries such as the United States and China.